Imakrebin

Imatinib, the active ingredient in Imakrebin, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, gastrointestinal stromal tumor, and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Imakrebin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imakrebin targets specific tyrosine‑kinase driven malignancies and is used in the following approved indications:

- Chronic myeloid leukemia (CML): Improves survival by inhibiting BCR‑ABL signaling. - Gastrointestinal stromal tumor (GIST): Reduces tumor growth by blocking c‑KIT activity. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Achieves remission through BCR‑ABL inhibition.

Imakrebin may cause a range of adverse reactions. Patients should be monitored regularly for any new symptoms.

Common Side Effects: - Nausea - Edema (peripheral swelling) - Fatigue - Muscle cramps or pain - Diarrhea - Rash or skin irritation

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe neutropenia or leukopenia - Cardiac failure or reduced left‑ventricular function - Pulmonary hypertension - Severe hemorrhage or gastrointestinal bleeding - Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should evaluate baseline organ function and counsel patients on potential risks.

- Monitor blood counts: Perform complete blood count (CBC) regularly to detect cytopenias. - Assess liver function: Check transaminases and bilirubin before and during treatment. - Evaluate cardiac status: Obtain baseline ECG and monitor for signs of heart failure. - Avoid use in patients with known hypersensitivity to imatinib: Discontinue if severe reaction occurs. - Store at ambient temperature: Keep in the original container, protect from moisture and light.

Imakrebin interacts with several drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase imatinib exposure and toxicity. - CYP3A4 inducers (e.g., rifampin): May reduce imatinib efficacy. - Warfarin: May potentiate anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - QT‑prolonging agents (e.g., quinidine): Monitor ECG for arrhythmia. - Diuretics (e.g., furosemide): May exacerbate fluid retention; watch for edema.